Roche gains global rights to a Rona Therapeutics RNA interference drug designed to target ALK7, a genetically validated target for obesity and other metabolic indications. The growing field of companies pursuing ALK7 includes GSK and Arrowhead Pharmaceuticals.
The post Roche Puts Up $100M to Pursue Promising But Competitive New Target in Obesity appeared first on MedCity News.
